What is the Knockout Mouse Project?

The Knockout Mouse Project (KOMP) was a large-scale, multi-institute effort to create a comprehensive collection of genetically engineered mouse strains, each lacking a specific gene. This project aimed to accelerate research by providing scientists with tools to study gene function and its role in various biological processes and diseases.

What is the significance of receiving a grant from the NIH?

Receiving a grant from the National Institutes of Health (NIH) signifies that Regeneron's research proposals and capabilities have met rigorous scientific review standards and are deemed important for advancing biomedical knowledge. It also provides significant funding that does not require giving up equity in the company.

How will this grant benefit Regeneron Pharmaceuticals?

The grant will provide substantial funding over five years, enabling Regeneron to advance its research in areas related to the Knockout Mouse Project. This financial support can be crucial for operational expenses, research personnel, and further development of its scientific platforms, without diluting existing shareholder ownership.

Does this grant relate to any specific Regeneron drugs or pipeline candidates?

The 8-K filing does not explicitly link the grant to specific current drugs or pipeline candidates. However, the Knockout Mouse Project is a fundamental research initiative that can inform the understanding of gene function, which is broadly applicable to drug discovery and development across various therapeutic areas.

REGN 8-K SEC Disclosure

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on September 8, 2006, to announce a significant development: the company was awarded a five-year grant from the National Institutes of Health (NIH) as part of the NIH’s Knockout Mouse Project. This grant represents a substantial non-dilutive funding source and acknowledges Regeneron's expertise in genetic research and development, particularly concerning mouse models.

Key Highlights

1Regeneron awarded a five-year grant from the National Institutes of Health (NIH).
2The grant is part of the NIH’s Knockout Mouse Project.
3This announcement signifies external validation of Regeneron's research capabilities.
4The grant provides a non-dilutive funding stream over a five-year period.
5The press release detailing this event is included as an exhibit to the 8-K filing.

REGENERON PHARMACEUTICALS, INC. 8-K Report, Corporate Update (Sep 8, 2006)

Summary

Key Highlights

Frequently Asked Questions